
feb pm et
summari develop small molecul therapeut treatment wide rang diseas led
cystic fibrosi anti-inflammatori condit
nm price-to-earnings oper ep
cour risk assess reflect view vertex
reliant expand cystic fibrosi cf franchis
wider patient sub-group given may write-down
hepat franchis see clear lead
market rival cf market
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
apr ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview biotechnolog compani focus discoveri
develop breakthrough small molecul drug seriou diseas compani product pipelin
focus viral diseas cystic fibrosi inflamm autoimmun diseas epilepsi
partnership cystic fibrosi foundat studi novel small molecul
treatment cystic fibrosi cf rare respiratori diseas afflict roughli patient world-wide
lead candid oral dose kalydeco approv januari treat adult cf
patient rare mutat repres around total patient popul
drug approv europ juli
orkambi lumacaftor combin ivacaftor approv unit state food drug
administr fda european commiss treatment patient cf
year age older two copi homozyg mutat cf
transmembran conduct regul cftr gene compani complet first two phase
clinic trial evalu lumacaftor combin ivacaftor treatment patient cf six
year age
homozyg mutat cftr gene
kalydeco ivacaftor orally-administ cftr potenti approv unit state
european union australia canada treatment certain patient cf specif
mutat cftr gene unit state kalydeco approv treatment patient
cf two year age older one mutat cftr gene includ
european union
kalydeco approv treatment patient cf two year age older one
follow mutat cftr gene
year age older mutat cftr gene
octob compani submit supplement new drug applic fda kalydeco
patient cf two year age older one residu function mutat
compani multipl develop program field cf includ corrector
compound evalu phase develop program combin ivacaftor multipl
cf patient popul least one copi mutat cftr gene
investig epitheli sodium channel enac inhibitor evalu phase
develop program exclus licens parion scienc inc parion
two next-gener cftr corrector compound enter phase clinic trial
fourth quarter plan evalu part combin treatment regimen
oral administ cftr corrector drug candid compani develop
combin ivacaftor
administr offic
offic presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
biosimilar drug approv set
exclus brand drug maker see
biosimilar advanc modest rate
next sever year march fda
approv novarti filgrastim biosimilar
sandoz began sell biosimilar
name zarxio septemb april
fda approv inflectra manufactur
celltrion co-market inflectra
biosimilar johnson johnson
remicad began ship inflectra
risk novemb discount
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug note prescript
benefit manag health insur
exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 year date
septemb biotech index
rose vs rise
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci
anticip limit sale growth
mainli due forecast
sale declin
robust growth period
compound annual growth rate think
sale growth somewhat limit
heighten focu high drug price
encourag view strong period
report late-stag clinic
result accommod fda
approv howev fda approv
new drug significantli
robust new drug approv
sinc record approv
think mani newly-approv drug
signific commerci prospect repres
major advanc therapi diseas
cystic fibrosi hepat multipl
sclerosi cancer expect wider
adopt biomark research
genetic-target clinic studi help
late fda introduc
speed develop promis program
expect favor merger acquisit
climat larg pharmaceut firm move
off-set lost revenu expir drug patent
larg biotech bolster drug pipelin
scale acquisit
industri bellweth becam first
biotech compani initi regular dividend
began dividend payment
establish fda author govern
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
improv plan file nda see combin drive
cf sale rais target in-lin peer
inc lower target
peer ratio base revis ep estim
set ep ep vs
estim sale rose orkambi sale
kalydeco sale fell guid orkambi sale
billion well initi forecast flat kalydeco sale
forecast revenu forecast part
depend obtain addit reimburs agreement sever
et capit iq keep hold opinion share vertex
lower target
peer revis ep estim
growth prospect ep vs loss
estim lower ep estim orkambi sale rose
kalydeco encourag pipelin progress announc
advanc phase ii trial
phase could part tripl combin treat
peopl cystic fibrosi current drug could treat half
analyst research note compani news
et cfra reiter buy opinion share vertex
pharmaceut incorpor rais
target above-p ratio robust growth prospect
rais ep estim set ep
vs ahead view cystic fibrosi cf product
sale grew orkambi kalydeco
tezacaftor/ivacaftor combin fda action date februari
expect approv select advanc phase
develop part two differ tripl combin regimen
think could treat cf patient /jeffrey loo cfa
et cfra rais opinion share vertex
inc buy hold keep target
peer ratio robust growth prospect cystic fibrosi
cf franchis sale cf drug rose orkambi kalydeco
ep vs ahead view rais
ep estim report mix
result phase trial orkambi children age meet
end-point trial evalu tezacaftor meet end-point
howev view tripl combin drug next catalyst cf
vertex pharmaceut incorpor announc appoint tom graney
role senior vice presid chief offic mr graney
begin role vertex septemb report execut
vice presid chief oper offic ian smith mr graney
respons develop execut financi strategi
oper support vertex busi plan includ financ
account intern audit function mr graney recent serv
cfo senior vice presid financ corpor strategi ironwood
inc rais target
peer share today releas data
separ compound use tripl drug combin approv
drug current treat cystic fibrosi cf patient
believ could treat cf patient tripl combin
drug separ phase ii combin studi improv lung
function phase trial improv lung function
impress result past posit data
vertex pharmaceut incorpor elect alan garber ph
independ member board director dr garber provost harvard
univers professor health polici harvard
medic school professor econom faculti art scienc
professor public polici harvard kennedi school govern
professor depart health polici manag harvard
 chan school public health prior join harvard dr
garber henri kaiser jr professor member nation
academi medicin american academi art scienc american
societi clinic investig associ american physician
board scienc technolog econom polici nation
et capit iq keep hold opinion share vertex
share posit data two
phase studi combin kalydeco treat cystic
fibrosi cf studi met primari end-point show
signific improv lung function evolv studi evalu patient
two copi mutat show improv
expand studi evalu patient one mutat show
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
